International Journal of Celiac Disease
ISSN (Print): 2334-3427 ISSN (Online): 2334-3486 Website: http://www.sciepub.com/journal/ijcd Editor-in-chief: Samasca Gabriel
Open Access
Journal Browser
Go
International Journal of Celiac Disease. 2019, 7(2), 48-52
DOI: 10.12691/ijcd-7-2-7
Open AccessArticle

The Facts of Celiac Disease; A Comprehensive Review

Nastaran Asri1 and Mohammad Rostami-Nejad2,

1Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Pub. Date: August 13, 2019

Cite this paper:
Nastaran Asri and Mohammad Rostami-Nejad. The Facts of Celiac Disease; A Comprehensive Review. International Journal of Celiac Disease. 2019; 7(2):48-52. doi: 10.12691/ijcd-7-2-7

Abstract

Celiac disease (CD) is the most common permanent T-cell mediated gluten intolerance, caused by the dietary gluten in individuals who are genetically susceptible to the disease. CD characterized by small intestine mucosal lesions, subtotal, or total intestinal villi atrophy and nutrient malabsorptions. Sometimes the diagnosis of CD is so challenging and needs a combination of clinical, serological, histopathological and genetic evaluations. The well-known cornerstone treatment of CD is gluten-free diet (GFD) and there is need to regular monitoring of patients after starting the GFD. The main aim of this review was to discussing the definition and pathogenesis of CD, together with the diagnostics, treatment and follow-up strategies in this disease.

Keywords:
celiac disease glutens t-lymphocytes diet gluten-free diagnosis

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Gasbarrini GB, Mangiola F, Gerardi V, Ianiro G, Corazza GR, Gasbarrini A. “Coeliac disease: an old or a new disease? History of a pathology.” Internal and emergency medicine 2014; 9(3): 249-256.
 
[2]  Ehsani-Ardakani MJ, Villanacci V, Volta U, Manenti S, Caio G, Giovenali P, Becheanu G, Diculescu M, Pellegrino S, Magazzù G. “Gastrointestinal and non-gastrointestinal presentation in patients with celiac disease.” Archives of Iranian medicine 2013; 16(2): 78.
 
[3]  Meresse B, Ripoche J, Heyman M, Cerf-Bensussan N. “Celiac disease: from oral tolerance to intestinal inflammation, autoimmunity and lymphomagenesis.” Mucosal immunology 2009; 2(1): 8.
 
[4]  Booth CC, Peters TJ, Doe WF. “Immunopathology of coeliac disease.” Ciba Found Symp 1977(46): 329-346
 
[5]  Kurada S, Yadav A, Leffler DA. “Current and novel therapeutic strategies in celiac disease.” Expert review of clinical pharmacology 2016; 9(9): 1211-1223.
 
[6]  Green PH, Lebwohl B, Greywoode R. “Celiac disease.” Journal of Allergy and Clinical Immunology 2015; 135(5): 1099-1106.
 
[7]  Marsh MN, Johnson MW, Rostami K. “Mucosal histopathology in celiac disease: a rebuttal of Oberhuber’s sub-division of Marsh III.” Gastroenterology and hepatology from bed to bench 2015; 8(2): 99.
 
[8]  Gujral N, Freeman HJ, Thomson AB. “Celiac disease: prevalence, diagnosis, pathogenesis and treatment.” World journal of gastroenterology: WJG 2012; 18(42): 6036.
 
[9]  Rostami MN, Karkhane M, Marzban A, Nazemalhosseini EM, Rostami K. “Gluten related disorders.” Gastroenterology and hepatology from bed to bench 2012; 5(Suppl 1): S1-7.
 
[10]  Schuppan D, Junker Y, Barisani D. “Celiac disease: from pathogenesis to novel therapies.” Gastroenterology 2009; 137(6): 1912-1933
 
[11]  Sollid LM, Khosla C. “Novel therapies for coeliac disease.” Journal of internal medicine 2011; 269(6): 604-613.
 
[12]  Green PH, Cellier C. “Celiac disease.” New england journal of medicine 2007; 357(17): 1731-1743.
 
[13]  Schumann M, Siegmund B, Schulzke JD, Fromm M. “Celiac disease: role of the epithelial barrier.” Cellular and molecular gastroenterology and hepatology 2017; 3(2): 150-162.
 
[14]  Ivarsson A, Hernell O, Stenlund H, Persson LÅ. “Breast-feeding protects against celiac disease.” The American journal of clinical nutrition 2002; 75(5): 914-921.
 
[15]  Hörnell A, Lagström H, Lande B, Thorsdottir I. “Breastfeeding, introduction of other foods and effects on health: a systematic literature review for the 5th Nordic Nutrition Recommendations.” Food & nutrition research 2013; 57(1): 20823.
 
[16]  Plugis NM, Khosla C. “Therapeutic approaches for celiac disease.” Best practice & research Clinical gastroenterology 2015; 29(3): 503-521.
 
[17]  Lewis D, Haridy J, Newnham ED. “Testing for coeliac disease.” Aust Prescr 2017; 40(3): 105-108.
 
[18]  Sugai E, Selvaggio G, Vazquez H, Viola M, Mazure R, Pizarro B, Smecuol E, Flores D, Pedreira S, Mauriño E. “Tissue transglutaminase antibodies in celiac disease: assessment of a commercial kit.” The American journal of gastroenterology 2000; 95(9): 2318.
 
[19]  Collin P, Mäki M, Keyriläinen O, Hällström O, Reunala T, Pasternack A. “Selective IgA deficiency and coeliac disease.” Scandinavian journal of gastroenterology 1992; 27(5): 367-371.
 
[20]  Rubio-Tapia A, Hill ID, Kelly CP, Calderwood AH, Murray JA. “ACG clinical guidelines: diagnosis and management of celiac disease.” The American journal of gastroenterology 2013; 108(5): 656.
 
[21]  Schuppan D, Zimmer K-P. “The diagnosis and treatment of celiac disease.” Deutsches Ärzteblatt International 2013; 110(49): 835.
 
[22]  Branski D. “New insights in celiac disease.” Rambam Maimonides medical journal 2012; 3(1).
 
[23]  Shannahan S, Leffler DA. “Diagnosis and Updates in Celiac Disease.” Gastrointest Endosc Clin N Am 2017; 27(1): 79-92.
 
[24]  Nilsen E, Lundin K, Krajci P, Scott H, Sollid L, Brandtzaeg P. “Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile dominated by interferon gamma.” Gut 1995; 37(6): 766-776.
 
[25]  Tripathi A, Lammers KM, Goldblum S, Shea-Donohue T, Netzel-Arnett S, Buzza MS, Antalis TM, Vogel SN, Zhao A, Yang S. “Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2.” Proceedings of the National Academy of Sciences 2009; 106(39): 16799-16804.
 
[26]  Fasano A, Not T, Wang W, Uzzau S, Berti I, Tommasini A, Goldblum SE. “Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease.” The Lancet 2000; 355(9214): 1518-1519.
 
[27]  Matysiak-Budnik T, Moura IC, Arcos-Fajardo M, Lebreton C, Ménard S, Candalh C, Ben-Khalifa K, Dugave C, Tamouza H, Van Niel G. “Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease.” Journal of Experimental Medicine 2008; 205(1): 143-154.
 
[28]  Monsuur AJ, de Bakker PI, Alizadeh BZ, Zhernakova A, Bevova MR, Strengman E, Franke L, van't Slot R, van Belzen MJ, Lavrijsen IC, Diosdado B, Daly MJ, Mulder CJ, Mearin ML, Meijer JW, Meijer GA, van Oort E, Wapenaar MC, Koeleman BP, Wijmenga C. “Myosin IXB variant increases the risk of celiac disease and points toward a primary intestinal barrier defect.” Nat Genet 2005; 37(12): 1341-1344.
 
[29]  Ontiveros N, Tye‐Din J, Hardy M, Anderson R. “Ex‐vivo whole blood secretion of interferon (IFN)‐γ and IFN‐γ‐inducible protein‐10 measured by enzyme‐linked immunosorbent assay are as sensitive as IFN‐γ enzyme‐linked immunospot for the detection of gluten‐reactive T cells in human leucocyte antigen (HLA)‐DQ 2· 5+‐associated coeliac disease.” Clinical & Experimental Immunology 2014; 175(2): 305-315.
 
[30]  Ménard S, Lebreton C, Schumann M, Matysiak-Budnik T, Dugave C, Bouhnik Y, Malamut G, Cellier C, Allez M, Crenn P. “Paracellular versus transcellular intestinal permeability to gliadin peptides in active celiac disease.” The American journal of pathology 2012; 180(2): 608-615.
 
[31]  Matysiak-Budnik T, Candalh C, Dugave C, Namane A, Cellier C, Cerf-Bensussan N, Heyman M. “Alterations of the intestinal transport and processing of gliadin peptides in celiac disease.” Gastroenterology 2003; 125(3): 696-707.
 
[32]  Ciccocioppo R, Di Sabatino A, Corazza GR. “The immune recognition of gluten in coeliac disease.” Clinical & Experimental Immunology 2005; 140(3): 408-416.
 
[33]  Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO, Schuppan D. “Identification of tissue transglutaminase as the autoantigen of celiac disease.” Nature medicine 1997; 3(7): 797.
 
[34]  Kim C-Y, Quarsten H, Bergseng E, Khosla C, Sollid LM. “Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease.” Proceedings of the National Academy of Sciences 2004; 101(12): 4175-4179.
 
[35]  Mazzarella G, Aufiero VR. “Immunoregulation in celiac disease.” Gastroenterology, Hepatology and Endoscopy 2016; 1(1): 13-17.
 
[36]  Borrelli M, Salvati VM, Maglio M, Zanzi D, Ferrara K, Santagata S, Ponticelli D, Aitoro R, Mazzarella G, Lania G. “Immunoregulatory pathways are active in the small intestinal mucosa of patients with potential celiac disease.” The American journal of gastroenterology 2013; 108(11): 1775.
 
[37]  Faghih M, Barartabar Z, Nasiri Z. “The role of Th1 and Th17 in the pathogenesis of celiac disease.” Gastroenterol Hepatol Open Access 2018; 9(2): 83-87.
 
[38]  Asri N, Rostami-Nejad M, Barzegar M, Nikzamir A, Rezaei-Tavirani M, Zali MR. Suppressive Mechanisms Induced by Treg Cells in Celiac Disease. Iranian Biomedical Journal. 2019; accepted.
 
[39]  Daum S, Bauer U, Foss H, Schuppan D, Stein H, Riecken E, Ullrich R. “Increased expression of mRNA for matrix metalloproteinases-1 and-3 and tissue inhibitor of metalloproteinases-1 in intestinal biopsy specimens from patients with coeliac disease.” Gut 1999; 44(1): 17-25.
 
[40]  Rauhavirta T, Qiao SW, Jiang Z, Myrsky E, Loponen J, Korponay‐Szabó I, Salovaara H, Garcia‐Horsman J, Venäläinen J, Männistö P. “Epithelial transport and deamidation of gliadin peptides: a role for coeliac disease patient immunoglobulin A.” Clinical & Experimental Immunology 2011; 164(1): 127-136.
 
[41]  Halttunen T, Mäki M. “Serum immunoglobulin A from patients with celiac disease inhibits human T84 intestinal crypt epithelial cell differentiation.” Gastroenterology 1999; 116(3): 566-572.
 
[42]  Barone MV, Caputo I, Ribecco MT, Maglio M, Marzari R, Sblattero D, Troncone R, Auricchio S, Esposito C. “Humoral immune response to tissue transglutaminase is related to epithelial cell proliferation in celiac disease.” Gastroenterology 2007; 132(4): 1245-1253.
 
[43]  Myrsky E, Caja S, Simon-Vecsei Z, Korponay-Szabo IR, Nadalutti C, Collighan R, Mongeot A, Griffin M, Mäki M, Kaukinen K. “Celiac disease IgA modulates vascular permeability in vitro through the activity of transglutaminase 2 and RhoA.” Cellular and molecular life sciences 2009; 66(20): 3375-3385.
 
[44]  Heydari F, Rostami-Nejad M, Moheb-Alian A, Mollahoseini MH, Rostami K, Pourhoseingholi MA, Aghamohammadi E, Zali MR. “Serum cytokines profile in treated celiac disease compared with non-celiac gluten sensitivity and control: a marker for differentiation.” Journal of Gastrointestinal & Liver Diseases 2018; 27(3).
 
[45]  Hüe S, Mention J-J, Monteiro RC, Zhang S, Cellier C, Schmitz J, Verkarre V, Fodil N, Bahram S, Cerf-Bensussan N. “A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease.” Immunity 2004; 21(3): 367-377.
 
[46]  Meresse B, Chen Z, Ciszewski C, Tretiakova M, Bhagat G, Krausz TN, Raulet DH, Lanier LL, Groh V, Spies T. “Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease.” Immunity 2004; 21(3): 357-366.
 
[47]  Forsberg G, Hernell O, Hammarström S, Hammarström M-L. “Concomitant increase of IL-10 and pro-inflammatory cytokines in intraepithelial lymphocyte subsets in celiac disease.” International immunology 2007; 19(8): 993-1001.
 
[48]  Meresse B, Curran SA, Ciszewski C, Orbelyan G, Setty M, Bhagat G, Lee L, Tretiakova M, Semrad C, Kistner E. “Reprogramming of CTLs into natural killer–like cells in celiac disease.” Journal of Experimental Medicine 2006; 203(5): 1343-1355.
 
[49]  Silvester JA, Rashid M. “Long-term follow-up of individuals with celiac disease: an evaluation of current practice guidelines.” Can J Gastroenterol 2007; 21(9): 557-564
 
[50]  Pietzak MM. “Follow-up of patients with celiac disease: achieving compliance with treatment.” Gastroenterology 2005; 128 (4 Suppl 1): S135-141.